venture capital – Talk Bio

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

17 hours ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

VC Funding Uptick in Back Half of 2025 Has Analysts Hopeful for 2026

17 hours ago talkbio0Tagged 2026, AI-driven, Attitude, Funding, Investments, IPO, M&A activity, MassBio, rates, venture capital, Vital capacity, Window (physical object)

venture capital; VC funding; 2025 H2; 2026 outlook; biotech; MassBio; IPO window; M&A activity; interest rates; AI-driven investment

Solve Therapeutics Raises $120M to Advance Next-Generation ADCs for Solid Tumors

2 months ago talkbio0Tagged Antibody-Drug Conjugates, Clinical Trials, CloakLink linker technology, Merck, Neoplasms, SLV-154, SLV-324, Solid Neoplasm, Solve Therapeutics, therapeutic autologous dendritic cells, venture capital, Yosemite

Solve Therapeutics; antibody-drug conjugates; ADC; CloakLink linker technology; solid tumors; oncology; SLV-154; SLV-324; clinical trials; venture capital; Yosemite; Merck

Spotlight On: VC Deal Flow – October’s Haul Sets 2025 up to Run Rings Around Previous Year

2 months ago talkbio0Tagged 2025, Deal Flow, Exit activity, funding rounds, Investments, Megadeals, October, Sector, Trail Making Test, Unicorn births, venture capital

Venture Capital; Deal Flow; 2025; October Funding; AI investment; Megadeals; Exit activity; TMT sector; Funding rounds; Unicorn births

Apptronik Raises $350 Million Series A to Scale AI Humanoid Robot Production

3 months ago talkbio0Tagged AI humanoid robots, Apollo robot, Apptronik, Funding, Robotics, Series A, venture capital

Apptronik; Series A funding; AI humanoid robots; Apollo robot; venture capital; robotics

Ascenta Capital Closes $325 Million Inaugural Fund to Back Exceptional Development-Stage Biotechs

3 months ago talkbio0Tagged Ascenta Capital, biotechs, Clinical Trials, Early-stage, Evan Rachlin, Funds, Investments, multi-medicine platforms, portfolio companies, venture capital

Ascenta Capital; biotech investment; venture capital; $325M fund; clinical trials; multi-medicine platforms; Evan Rachlin; Lorence Kim; early-stage biotechs; portfolio companies

Getting to Yes: How Deal-Making Fuels Biotech Growth – 2025 Updates

4 months ago talkbio0Tagged Acquisitions, BATNA, biotech dealmaking, Licensing, mergers, patent cliffs, pharmaceutical negotiations, pipeline gaps, regulatory uncertainty, reputation, valuation, venture capital

biotech dealmaking; mergers and acquisitions; licensing; venture capital; BATNA; pharmaceutical negotiations; reputation; pipeline gaps; patent cliffs; valuation; regulatory uncertainty

Sanofi Injects $625M Into Biotech Investment Arm to Accelerate Innovation

4 months ago talkbio0Tagged Cash, cell/gene therapy, digital health, expansion, Immunology, Infrequent, Infusion procedures, Investments, Neurology speciality, portfolio, sanofi, Sanofi Ventures, venture capital

Sanofi; Sanofi Ventures; biotech investment; $625M cash infusion; digital health; immunology; rare diseases; neurology; venture capital; cell/gene therapy; portfolio expansion

Fierce Biotech Fundraising Tracker ’25: Avenzo adds $60M Series B; Ollin debuts with $100M

4 months ago talkbio0Tagged Antibodies, Bispecific, Avenzo, Clinical Trials, Neoplasms, Ollin Biosciences, Ophthalmology specialty, pipeline development, Series B financing, venture capital

Avenzo Therapeutics; Series B financing; Ollin Biosciences; biotech fundraising; oncology; ophthalmology; venture capital; pipeline development; bispecific antibody; clinical trials

Langers Team Launch $77.5M Fund to Invest at Intersection of Technology and Biology

4 months ago talkbio0Tagged biology (field), Capital, Fund I, Geographic Intersection, Investments, Michael Langer, Robert Langer, Technology, venture capital

T.Rx Capital; Robert Langer; Michael Langer; intersection of technology and biology; biotech investments; venture capital; Fund I